Skip to main content

Table 2 Dialysis condition

From: Improvement of the fraction of human mercaptalbumin on hemodialysis treatment using hydrogen-dissolved hemodialysis fluid: a prospective observational study

 

EW-HD (n = 12) EWHD2014 → EWHD015

C-HD (n = 38)

Notes

Treatment mode

Hemodialysis

Hemodialysis

 

Treatment time (hour/session)

3.92 ± 0.19 → 3.96 ± 0.14

3.95 ± 0.48

Mean ± SD ns

Hemodialysis frequency

3 times/week

3 times/week

 

Dialyzer type/membrane material

V/PS: 6; IV/CTA: 6 → V/PS: 7; IV/CTA: 5

V/PS: 14; IV/PS: 8, CTA: 16

Polysulfone (PS), cellulose triacetate (CTA)

Dialyzer membrane area (m2)

1.5 (1.3–2.1) → 1.7 (1.5–2.1)

1.8 (1.3–2.5)

Median (min−max) ns

QB (mL/min)

200 (180–230) → 200 (200–230)

200 (150–250)

Median (min−max) ns

QD (mL/min)

500

500

 

Dialysis dose: KT/V for urea

1.45 ± 0.15 → 1.55 ± 0.19

1.45 ± 0.24

Mean ± SD ns

Body weight pre-HD (kg)

52.9 ± 6.4 → 54.3 ± 6.3

56.6 ± 11.5

Mean ± SD ns

       post-HD (kg)

50.7 ± 6.4 → 51.9 ± 6.5

54.1 ± 10.9

Mean ± SD ns

Dialysis powder

D DRY®-2.5S/3.0S

Kindaly 4E

 

Compositions of hemodialysis fluid

   

 Na+ (mEq/L)

140.0

140.0

 

 K+ (mEq/L)

2.0

2.0

 

 Ca2+ (mEq/L)

2.75

2.75

 

 Mg2+ (mEq/L)

1.0

1.0

 

 Cl (mEq/L)

112.25

112.25

 

 HCO3 (mEq/L)

25.0

27.5

 

 CH3COO (mEq/L)

10.0

8.0

 

 C6H12O6 (mg/dL)

100.0

125.0

 
  1. ns no significant difference between EW-HD and C-HD